Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blinded, Placebo Controlled, Crossover Infusion Study of Respiratory Pharmacodynamics of ENA-001 in Conjunction with Propofol, Hypoxia, and Hypercapnia

Next Previous
Trial Profile

A Double Blinded, Placebo Controlled, Crossover Infusion Study of Respiratory Pharmacodynamics of ENA-001 in Conjunction with Propofol, Hypoxia, and Hypercapnia

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ENA-001 (Primary) ; Propofol
  • Indications Hypoxia; Respiration disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms CHDR2119
  • Sponsors Enalare Therapeutics

Most Recent Events

  • 01 Jun 2024 Results (n=12) assessing reversal of propofol-induced depression of the hypoxic ventilatory response by BK-channel blocker published in the Anesthesiology
  • 22 Aug 2023 According to a Enalare Therapeutics media release, data assessing how ENA-001 restores the bodies ventilatory control sensitivity blunted by propofol (i.e., a non-opioid central depressant) by acting on the peripheral chemoreceptors and the pharmacokinetic-pharmacodynamic modeling from this trial will be presented at the American Society of Anesthesiologists (ASA) Annual Meeting 2023.
  • 28 Sep 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top